Serum microRNAs as biomarkers for recurrence in melanoma

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Friedman, Erica B ^a   Shang, Shulian ^a   de Miera, Eleazar V ^a   Fog, Jacob U ^b   Teilum, Maria W ^b   Ma, Michelle W ^a   Berman, Russell S ^a   Shapiro, Richard L ^a   Pavlick, Anna C ^a   Hernando, Eva ^a   Baker, Adam ^b   Shao, Yongzhao ^a   Osman, Iman ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Exiqon AS   (Denmark)

Author keywords

Melanoma; Prognostic biomarkers; Recurrence; Serum microRNA; Surveillance

Indexed keywords

MICRORNA;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURGERY; COHORT ANALYSIS; DIAGNOSTIC ACCURACY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; PATIENT MONITORING; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RECURRENT CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; VALIDATION PROCESS;

FEMALE; HUMANS; MALE; MELANOMA; MICRORNAS; MIDDLE AGED; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84864486967     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-155     Document Type: Article

References (52)

1. SEER Cancer Statistics Review, 1975-2008 [Internet] [http://seer.cancer.gov/csr/1975_2008/].
2. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004, 351:998-1012. 10.1056/NEJMra041245, 15342808.
3. Garbe C. A rational approach to the follow-up of melanoma patients. Recent Results Cancer Res 2002, 160:205-215. 10.1007/978-3-642-59410-6_24, 12079215.
4. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Kirkwood JM, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001, 19:3635-3648.
5. Leiter U, Buettner PG, Eigentler TK, Forschner A, Meier F, Garbe C. Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit?. Melanoma Res 2010, 20:240-246.
6. Grange F, Vitry F, Granel-Brocard F, Lipsker D, Aubin F, Hédelin G, Dalac S, Truchetet F, Michel C, Batard ML, et al. Variations in management of stage I to stage III cutaneous melanoma: a population-based study of clinical practices in France. Arch Dermatol 2008, 144:629-636. 10.1001/archderm.144.5.629, 18490589.
7. Hofmann U, Szedlak M, Rittgen W, Jung EG, Schadendorf D. Primary staging and follow-up in melanoma patients-monocenter evaluation of methods, costs and patient survival. Br J Cancer 2002, 87:151-157. 10.1038/sj.bjc.6600428, 2376106, 12107834.
8. Bast RC, Ravdin P, Hayes DF, Bates S, Fritsche H, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001, 19:1865-1878.
9. Berger AJ, Camp RL, Divito KA, Kluger HM, Halaban R, Rimm DL. Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome. Cancer Res 2004, 64:8767-8772. 10.1158/0008-5472.CAN-04-1384, 15574789.
10. Deichmann M, Benner A, Bock M, Jäckel A, Uhl K, Waldmann V, Näher H. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 1999, 17:1891-1896.
11. Tarhini AA, Stuckert J, Lee S, Sander C, Kirkwood JM. Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol 2009, 27:38-44. 10.1200/JCO.2009.21.8271, 3426933, 19047287.
12. Garbe C, Paul A, Kohler-Spath H, Ellwanger U, Stroebel W, Schwarz M, Schlagenhauff B, Meier F, Schittek B, Blaheta HJ, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol 2003, 21:520-529. 10.1200/JCO.2003.01.091, 12560444.
13. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297. 10.1016/S0092-8674(04)00045-5, 14744438.
14. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838. 10.1038/nature03702, 15944708.
15. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008, 105:10513-10518. 10.1073/pnas.0804549105, 2492472, 18663219.
16. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat Rev Clin Oncol 2011, 8:467-477. 10.1038/nrclinonc.2011.76, 3423224, 21647195.
17. Cortez MA, Calin GA. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther 2009, 9:703-711. 10.1517/14712590902932889, 19426115.
18. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008, 141:672-675. 10.1111/j.1365-2141.2008.07077.x, 18318758.
19. Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, Harris CC, Chen K, Hamilton SR, Zhang W. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One 2011, 6:e17745. 10.1371/journal.pone.0017745, 3060165, 21445232.
20. Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, Zen K, Zhang C, Shen H. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010, 28:1721-1726. 10.1200/JCO.2009.24.9342, 20194856.
21. Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, Calabro E, Croce CM, Pastorino U, Sozzi G. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A 2011, 108:3713-3718. 10.1073/pnas.1100048108, 3048155, 21300873.
22. Wich LG, Hamilton HK, Shapiro RL, Pavlick A, Berman RS, Polsky D, Goldberg JD, Hernando E, Manga P, Krogsgaard M, et al. Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research. Am J Transl Res 2009, 1:35-43. 2776290, 19966936.
23. Jensen SG, Lamy P, Rasmussen MH, Ostenfeld MS, Dyrskjot L, Orntoft TF, Andersen CL. Evaluation of two commercial global miRNA expression profiling platforms for detection of less abundant miRNAs. BMC Genomics 2011, 12:435. 10.1186/1471-2164-12-435, 3184117, 21867561.
24. Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S, Enzo E, Guzzardo V, Rondina M, Spruce T, et al. A MicroRNA targeting dicer for metastasis control. Cell 2010, 141:1195-1207. 10.1016/j.cell.2010.05.017, 20603000.
25. He Y, Cui Y, Wang W, Gu J, Guo S, Ma K, Luo X. Hypomethylation of the hsa-miR-191 locus causes high expression of hsa-mir-191 and promotes the epithelial-to-mesenchymal transition in hepatocellular carcinoma. Neoplasia 2011, 13:841-853. 3182276, 21969817.
26. Liu R, Zhang C, Hu Z, Li G, Wang C, Yang C, Huang D, Chen X, Zhang H, Zhuang R, et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer 2011, 47:784-791. 10.1016/j.ejca.2010.10.025, 21112772.
27. Segura MF, Hanniford D, Menendez S, Reavie L, Zou X, Alvarez-Diaz S, Zakrzewski J, Blochin E, Rose A, Bogunovic D, et al. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci U S A 2009, 106:1814-1819. 10.1073/pnas.0808263106, 2634798, 19188590.
28. Felicetti F, Errico MC, Segnalini P, Mattia G, Care A. MicroRNA-221 and -222 pathway controls melanoma progression. Expert Rev Anticancer Ther 2008, 8:1759-1765. 10.1586/14737140.8.11.1759, 18983236.
29. Klein J, Moeschberger M. Survival Analysis: Techniques for Censored and Truncated Data 1997, Springer-Verlag, New York, 1.
30. Wang Y, Chen H, Li R, Duan N, Lewis-Fernandez R. Prediction-Based Structured Variable Selection through the Receiver Operating Characteristic Curves. Biometrics 2011, 67:896-905. 10.1111/j.1541-0420.2010.01533.x, 3134557, 21175555.
31. Satzger I, Mattern A, Kuettler U, Weinspach D, Voelker B, Kapp A, Gutzmer R. MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma. Int J Cancer 2010, 126:2553-2562.
32. Poo-Hwu WJ, Ariyan S, Lamb L, Papac R, Zelterman D, Hu GL, Brown J, Fischer D, Bolognia J, Buzaid AC. Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma. Cancer 1999, 86:2252-2258. 10.1002/(SICI)1097-0142(19991201)86:11<2252::AID-CNCR12>3.0.CO;2-Q, 10590365.
33. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27:6199-6206. 10.1200/JCO.2009.23.4799, 2793035, 19917835.
34. Duffy MJ. Role of tumor markers in patients with solid cancers: A critical review. Eur J Intern Med 2007, 18:175-184. 10.1016/j.ejim.2006.12.001, 17449388.
35. Leidinger P, Keller A, Borries A, Reichrath J, Rass K, Jager SU, Lenhof HP, Meese E. High-throughput miRNA profiling of human melanoma blood samples. BMC Cancer 2010, 10:262. 10.1186/1471-2407-10-262, 2889897, 20529253.
36. Mueller DW, Rehli M, Bosserhoff AK. miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J Invest Dermatol 2009, 129:1740-1751. 10.1038/jid.2008.452, 19212343.
37. Caramuta S, Egyhazi S, Rodolfo M, Witten D, Hansson J, Larsson C, Lui WO. MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J Invest Dermatol 2010, 130:2062-2070. 10.1038/jid.2010.63, 20357817.
38. Philippidou D, Schmitt M, Moser D, Margue C, Nazarov PV, Muller A, Vallar L, Nashan D, Behrmann I, Kreis S. Signatures of microRNAs and selected microRNA target genes in human melanoma. Cancer Res 2010, 70:4163-4173. 10.1158/0008-5472.CAN-09-4512, 20442294.
39. Segura MF, Belitskaya-Levy I, Rose AE, Zakrzewski J, Gaziel A, Hanniford D, Darvishian F, Berman RS, Shapiro RL, Pavlick AC, et al. Melanoma MicroRNA signature predicts post-recurrence survival. Clin Cancer Res 2010, 16:1577-1586. 10.1158/1078-0432.CCR-09-2721, 20179230.
40. Kanemaru H, Fukushima S, Yamashita J, Honda N, Oyama R, Kakimoto A, Masuguchi S, Ishihara T, Inoue Y, Jinnin M, Ihn H. The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J Dermatol Sci 2011, 61:187-193. 10.1016/j.jdermsci.2010.12.010, 21273047.
41. Srivastava SK, Bhardwaj A, Singh S, Arora S, Wang B, Grizzle WE, Singh AP. MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells. Carcinogenesis 2011, 32:1832-1839. 10.1093/carcin/bgr223, 21983127.
42. Wu Q, Jin H, Yang Z, Luo G, Lu Y, Li K, Ren G, Su T, Pan Y, Feng B, et al. MiR-150 promotes gastric cancer proliferation by negatively regulating the pro-apoptotic gene EGR2. Biochem Biophys Res Commun 2010, 392:340-345. 10.1016/j.bbrc.2009.12.182, 20067763.
43. Ghisi M, Corradin A, Basso K, Frasson C, Serafin V, Mukherjee S, Mussolin L, Ruggero K, Bonanno L, Guffanti A, et al. Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150. Blood 2011, 117:7053-7062. 10.1182/blood-2010-12-326629, 21551231.
44. Sun L, Yao Y, Liu B, Lin Z, Lin L, Yang M, Zhang W, Chen W, Pan C, Liu Q, et al. MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene 2012, 31:432-445. 10.1038/onc.2011.263, 21725369.
45. Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun S, Hong L, Liu J, Fan D. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008, 123:372-379. 10.1002/ijc.23501, 18449891.
46. Li Z, Gu X, Fang Y, Xiang J, Chen Z. microRNA expression profiles in human colorectal cancers with brain metastases. Oncol Lett 2012, 3:346-350.
47. Sakurai K, Furukawa C, Haraguchi T, Inada K, Shiogama K, Tagawa T, Fujita S, Ueno Y, Ogata A, Ito M, et al. MicroRNAs miR-199a-5p and -3p target the Brm subunit of SWI/SNF to generate a double-negative feedback loop in a variety of human cancers. Cancer Res 2011, 71:1680-1689. 10.1158/0008-5472.CAN-10-2345, 21189327.
48. Thomas M, Lange-Grünweller K, Weirauch U, Gutsch D, Aigner A, Grünweller A, Hartmann RK. The proto-oncogene Pim-1 is a target of miR-33a. Oncogene 2012, 31:918-928. 10.1038/onc.2011.278, 21743487.
49. Cirera-Salinas D, Pauta M, Allen RM, Salerno AG, Ramírez CM, Chamorro-Jorganes A, Wanschel AC, Lasuncion MA, Morales-Ruiz M, Suarez Y, et al. Mir-33 regulates cell proliferation and cell cycle progression. Cell Cycle 2012, 11: .
50. Ghosh G, Subramanian IV, Adhikari N, Zhang X, Joshi HP, Basi D, Chandrashekhar YS, Hall JL, Roy S, Zeng Y, Ramakrishnan S. Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF-α isoforms and promotes angiogenesis. J Clin Invest 2010, 120:4141-4154. 10.1172/JCI42980, 2964978, 20972335.
51. Rosa A, Ballarino M, Sorrentino A, Sthandier O, De Angelis FG, Marchioni M, Masella B, Guarini A, Fatica A, Peschle C, Bozzoni I. The interplay between the master transcription factor PU.1 and miR-424 regulates human monocyte/macrophage differentiation. Proc Natl Acad Sci U S A 2007, 104:19849-19854. 10.1073/pnas.0706963104, 2148386, 18056638.
52. Simon R. Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 2005, 23:7332-7341. 10.1200/JCO.2005.02.8712, 16145063.